TNF and rheumatoid arthritis: In the various clinical trials involving RA patients, anti-TNF biologics administered along with methotrexate have achieved ACR50 response (50% improvement in a standard set of measures of disease) in only 18–48% of participants by 6 mo (Johnson et al., 2019).